Question 1

What is Nivolumab?

Accepted Answer

Nivolumab is a monoclonal antibody that works by blocking a specific protein called PD-1 found on certain immune cells. This protein normally acts as a checkpoint that prevents the immune system from attacking cells.

By blocking this protein, the medication prevents cancer cells from hiding from the body's natural defenses. This allows the immune system to more effectively identify and destroy cancer cells throughout the body.

Question 2

What is Nivolumab used for?

Accepted Answer

Nivolumab is used to treat:

Melanoma

Non-small cell lung cancer

Renal cell carcinoma

Others

Question 3

How does Nivolumab work?

Accepted Answer

Immune System Activation

Nivolumab belongs to a class of drugs known as monoclonal antibodies and immune checkpoint inhibitors. Its primary role is to boost the body's natural immune response against cancer cells.

Targeting the PD-1 Pathway

The immune system uses specific "checkpoints" to prevent it from attacking healthy cells. One of these checkpoints involves a protein called programmed death-1 (PD-1) found on the surface of T-cells, which are a type of white blood cell. When certain proteins on cancer cells bind to PD-1, they send a signal to the T-cell to stop its attack, effectively allowing the cancer to hide from the immune system.

Nivolumab works by:

Blocking the PD-1 receptor: The medication attaches to the PD-1 protein on the T-cells.

Preventing the "off" signal: By blocking this receptor, nivolumab prevents cancer cells from binding to the T-cells and switching them off.

Restoring immune function: This allows the T-cells to remain active so they can find, target, and destroy cancer cells throughout the body.

In some treatment plans, nivolumab is used in combination with other immunotherapy drugs to further enhance the immune system's ability to recognize and fight specific types of tumors.

Question 4

What are the brand names for Nivolumab?

Accepted Answer

Nivolumab is sold under the brand name Opdivo .

Question 5

What are the active ingredients in Nivolumab?

Accepted Answer

The active ingredient in Nivolumab is nivolumab .

Question 6

What are the side effects of Nivolumab?

Accepted Answer

Common side effects of Nivolumab may include:

fatigue

rash

itching

and others

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Nivolumab?

Accepted Answer

Nivolumab belongs to the PD-1 inhibitor drug class.

Question 8

What is the dosage of Nivolumab and how do I take it?

Accepted Answer

Administration

Nivolumab is given by a healthcare professional in a medical setting, such as a hospital or infusion clinic. It is administered in one of the following ways:

Intravenous (IV) Infusion: The medication is delivered into a vein through a needle or catheter. This process typically takes between 30 and 60 minutes.

Subcutaneous Injection: Certain formulations of this medication may be injected just under the skin, usually in the thigh or abdomen.

Treatment Schedule

Nivolumab is usually given in cycles. Depending on the specific diagnosis and whether it is used alone or in combination with other medications, it may be administered every two, three, four, or six weeks. Your healthcare provider will determine the appropriate schedule and the total duration of your treatment.

Missed Doses

If you miss an appointment for a nivolumab treatment, contact your healthcare provider immediately to reschedule. It is important to receive each dose as scheduled to ensure the medication is as effective as possible.

Preparation

Before receiving nivolumab, your doctor may perform blood tests to ensure it is safe for you to receive the medication. You may also receive other medications before the infusion to help prevent certain side effects.

Question 9

Is Nivolumab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Nivolumab can cause harm to an unborn baby. It is important to inform a healthcare provider if you are pregnant or planning to become pregnant before starting this medication. Individuals who can become pregnant should use effective birth control during treatment and for at least 5 months after the final dose of nivolumab.

Breastfeeding

It is not known whether nivolumab passes into human breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is not recommended during treatment. Patients are generally advised to avoid breastfeeding while receiving nivolumab and for at least 5 months after the last dose.

Question 10

What forms and strengths does Nivolumab come in?

Accepted Answer

Available Forms

Nivolumab is supplied in the following formulations for administration by medical staff:

Intravenous Infusion: This form is a concentrated liquid solution that must be diluted before being infused into a vein.

Subcutaneous Injection: This formulation combines nivolumab with hyaluronidase and is designed for injection under the skin.

Both formulations are provided in vials and are administered in a clinical setting, such as a hospital or infusion center.

Question 11

What is the FDA approval status of Nivolumab?

Accepted Answer

FDA Approval Status

Nivolumab was first approved by the U.S. Food and Drug Administration (FDA) in December 2014. It is a programmed death receptor-1 (PD-1) blocking antibody. Since its initial approval, the FDA has expanded its use to include numerous types of cancer, often as a first-line or second-line treatment depending on the specific diagnosis and previous therapies.

Approved Indications

The FDA has approved nivolumab for several adult and pediatric indications, including:

Unresectable or metastatic melanoma.

Metastatic non-small cell lung cancer.

Malignant pleural mesothelioma.

Advanced renal cell carcinoma.

Classical Hodgkin lymphoma.

Squamous cell carcinoma of the head and neck.

Urothelial carcinoma (bladder cancer).

Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.

Hepatocellular carcinoma (liver cancer).

Esophageal and gastric cancers.

Recent Regulatory Actions

In February 2025, the FDA approved a subcutaneous formulation of nivolumab and hyaluronidase-nvhy. This formulation is approved for many of the same indications as the intravenous version, offering a shorter administration time. Additionally, the FDA has approved specific combination therapies, such as nivolumab used with ipilimumab, for patients with certain types of liver cancer and colorectal cancer that have progressed after prior treatments.

Safety and Monitoring

Nivolumab does not currently carry a Boxed Warning. However, the FDA-approved labeling includes significant warnings regarding immune-mediated adverse reactions. These reactions can occur in the lungs, colon, liver, endocrine system, kidneys, or skin. Because these reactions can be severe or life-threatening, the FDA requires healthcare providers to monitor patients closely during and after treatment. Some approvals were granted under the accelerated approval pathway based on tumor response rate and durability of response, and continued approval may be contingent upon verification of clinical benefit in confirmatory trials.

Question 12

What should I know about Nivolumab and cost?

Accepted Answer

Factors Influencing Cost

The total cost of nivolumab treatment depends on several factors, including the specific medical condition being treated and the required dosage. Because the medication is administered by a healthcare professional in a clinical setting, costs typically include both the drug itself and fees for the medical facility and professional services.

Administration Method: Nivolumab may be given as an intravenous infusion or a subcutaneous injection, which can affect the overall cost of administration.

Combination Therapy: In many cases, nivolumab is used alongside other medications, such as ipilimumab, which will increase the total cost of the treatment cycle.

Insurance and Financial Support

Most insurance plans, including Medicare and Medicaid, provide coverage for nivolumab when used for FDA-approved indications. However, patients may be responsible for out-of-pocket costs such as deductibles or co-payments. Many pharmaceutical companies offer patient assistance programs or co-pay cards to help eligible individuals manage these expenses.

Nivolumab

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?